Returning guest Dr. Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor. ...
The Uromigos: Kidney Cancer
Hear Thomas Powles, MD, and Brian Rini, MD, FASCO, discuss research and news on kidney cancer.
Advertisement
Dr. Vincent Xu of Dana-Farber Cancer Institute discusses this emerging RCC biomarker and data from the Checkmate 214 trial.
Returning guest Dr. Laurence Albiges discusses novel combos in refractory RCC and gives an update on COSMIC-313.
David Braun, MD, PhD joins the show to discuss his Nature paper on a personalized RCC vaccine.
Professor Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy in RCC tumors.
Dr. David McDermott joins the podcast to review the top data from 2024 in the renal cell carcinoma field.
Dr. Jim Brugarolas joins the podcast to discuss his talk from IKCS 2024 and the broad topic of resistance to HIF inhibitors.
Dr. Andrew Smith, chair of diagnostic imaging at St. Jude's, joins the podcast to discuss the emerging field of radiomics.
Listen to the podcast format of the kidney cancer panel on IO after IO therapy from Uromigos Live 2024.
Listen to the podcast format of the kidney cancer panel on TKI vs Ipi/Nivo vs IO/TKI from Uromigos Live 2024.
Tom and Brian finish discussing bladder and kidney cancer highlights from ESMO 2024.
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC.
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon discuss recent ESMO guideline changes on GU cancers.
Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics.
Dr. Eric Jonasch discusses the process of guideline modification and updates in adjuvant, front-line and refractory RCC.
Dr. David Braun discusses his organization of immune therapies into four groups and describes novel treatments and targets.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon host the first Spanish-language ASCO episode for The Uromigos.
Drs. Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden get a chance to win The Uromigos Cup.
Drs. Viktor Grünwald, Boris Hadaschik and Gunhild Von Amsberg answer trivia for the Uromigos Cup qualifying round.
Drs. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura answer trivia questions set by Tom and Brian for the Uromigos Cup.
Drs. Danny Heng, Christian Kollmannsberger and Kala Sridhar attempt to take on Team LA to win the Uromigos Cup.
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564.
Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments.
Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data.
Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC.
Cristina Suarez discusses the biggest RCC trials of 2023.
Tian Zhang joins the podcast to give an overview of some of the panels presented at this year's IKCS meeting.
Xinan Sheng, MD, joins the podcast to discuss the RENOTORCH trial on toripalimab plus axitinib for advanced RCC.
Dr. Lisa Pickering discusses 3 different renal cancer abstracts that were presented at ESMO 2023.
Dr. Toni Choueiri discusses progress in systemic therapy for papillary renal cell carcinoma, as well as personalized therapy.
Dr. Celeste Simon discusses her career in translational science and kidney cancer at the University of Pennsylvania.
Dr. Laurence Albiges discusses biomarker studies and new combinations and therapies presented at the KCRS23 meeting.
Rachel Giles, MD, PhD, describes her patient data on adjuvant and first line treatments in renal cell carcinoma.
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.
Bob Motzer, MD, joins the discussion on IPI/Nivo versus VEGF/PD1 to give his perspective on the recent debate from ASCO 2023.
The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD.
Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC.
Dr. Daniel Heng joins us to discuss IMDC classification for RCC and the treatment of patients with favorable risk disease.
Toni Choueiri, MD, and Brian Shuch, MD, discuss several studies on the use of belzutifan in patients with renal cancer.
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
Brian Shuch, MD, discusses the ZIRCON Phase III imaging study on identification and characterization abilities of TLX250-CDx.
A summary of the renal cancer session of the Conversations & Trending Topics in GU Cancers conference in the Canary Islands.
Monty Pal, MD, FASCO, discusses his recent study on the use of novel CAR T-cell therapy for renal cell carcinoma.
David McDermott, MD, debates the role of ipilimumab for clear cell renal cancer with Uromigos host Brian Rini, MD.
Pavlos Msaouel chats with The Uromigos about his editorial on the results of the recent COSMIC-313 trial.
The Uromigos chat with Dan Shapiro, Assistant Professor of Urologic Oncology, on his work in renal medullary carcinoma.
The Uromigos chat with Scott M. Haake for the second episode of their Rising Star series and discuss his latest project.
The Rising Star series starts with Renee Saliby, a postdoctoral GU oncology research fellow at Dana-Farber Cancer Institute.
Toni Choueiri describes the COSMIC-313 trial on cabozantinib with nivolumab and ipilimumab in advanced or metastatic RCC.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.